Skip to main content

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

May 2011 - FRMC

Feature
05/24/2011
Minneapolis—In a single-arm, multicenter, observational study of patients in the United States with type 2 diabetes (T2D), twice-daily administration of exenatide was associated with significantly lower glycosylated hemoglobin (A1c) test...
Minneapolis—In a single-arm, multicenter, observational study of patients in the United States with type 2 diabetes (T2D), twice-daily administration of exenatide was associated with significantly lower glycosylated hemoglobin (A1c) test...
Minneapolis—In a single-arm,...
05/24/2011
First Report Managed Care
Department
05/24/2011
Minneapolis—When the US Food and Drug Administration (FDA) approved interferon beta-1b, a biotechnology product, in 1993, the treatment approach regarding multiple sclerosis (MS) changed, according to Gary M. Owens, MD, president of Gary...
Minneapolis—When the US Food and Drug Administration (FDA) approved interferon beta-1b, a biotechnology product, in 1993, the treatment approach regarding multiple sclerosis (MS) changed, according to Gary M. Owens, MD, president of Gary...
Minneapolis—When the US Food and...
05/24/2011
First Report Managed Care
Department
05/24/2011
Minneapolis—In a contemporary issues session at the AMCP meeting titled Specialty Pharmaceuticals Pipeline Update, attendees heard from Aimee Tharaldson, PharmD, senior clinical consultant, emerging therapeutics, at Express Scripts. Dr....
Minneapolis—In a contemporary issues session at the AMCP meeting titled Specialty Pharmaceuticals Pipeline Update, attendees heard from Aimee Tharaldson, PharmD, senior clinical consultant, emerging therapeutics, at Express Scripts. Dr....
Minneapolis—In a contemporary...
05/24/2011
First Report Managed Care
Department
05/23/2011
The number of products in the pharmaceutical pipeline is less than it was from 2007 through 2009.
The number of products in the pharmaceutical pipeline is less than it was from 2007 through 2009.
The number of products in the...
05/23/2011
First Report Managed Care
Feature
05/23/2011
Minneapolis—The initiation of pregabalin, which is typically prescribed as adjunctive therapy in patients who experience seizures and as relief for neuropathic pain in patients with diabetes, postherpetic neuralgia, or fibromyalgia,...
Minneapolis—The initiation of pregabalin, which is typically prescribed as adjunctive therapy in patients who experience seizures and as relief for neuropathic pain in patients with diabetes, postherpetic neuralgia, or fibromyalgia,...
Minneapolis—The initiation of...
05/23/2011
First Report Managed Care
Feature
05/23/2011
Minneapolis—Although growth in the US pharmaceutical market slowed from a 5.2% sales increase in 2009 to a 2.3% sales increase in 2010, the market was “pretty resilient,” according to Doug Long, MBA, vice president of industry relations at...
Minneapolis—Although growth in the US pharmaceutical market slowed from a 5.2% sales increase in 2009 to a 2.3% sales increase in 2010, the market was “pretty resilient,” according to Doug Long, MBA, vice president of industry relations at...
Minneapolis—Although growth in...
05/23/2011
First Report Managed Care

Department

Conference Insider
05/23/2011
Organizing care involves the marshalling of personnel and other resources needed to carry out all required patient care activities.
Organizing care involves the marshalling of personnel and other resources needed to carry out all required patient care activities.
Organizing care involves the...
05/23/2011
First Report Managed Care
Conference Insider
05/23/2011
The Affordable Care Act of 2010 places emphasis on the use of health information technology and its potential to reduce healthcare costs and improve health outcomes. 
The Affordable Care Act of 2010 places emphasis on the use of health information technology and its potential to reduce healthcare costs and improve health outcomes. 
The Affordable Care Act of 2010...
05/23/2011
First Report Managed Care
Conference Insider
05/23/2011
Minneapolis—Approved by the US Food and Drug Administration (FDA) in 1954, warfarin has been the standard of care for decades for many patients with thromboembolic disorders. Still, some physicians are reluctant to prescribe warfarin because...
Minneapolis—Approved by the US Food and Drug Administration (FDA) in 1954, warfarin has been the standard of care for decades for many patients with thromboembolic disorders. Still, some physicians are reluctant to prescribe warfarin because...
Minneapolis—Approved by the US...
05/23/2011
First Report Managed Care
Conference Insider
05/23/2011
Minneapolis—At a pharmacy partnership briefing session at the AMCP meeting, 2 pharmacists discussed medication therapy management (MTM) as it relates to Medicare Part D in a presentation titled MTM: Medicare Part D and Beyond. Jessica Frank,...
Minneapolis—At a pharmacy partnership briefing session at the AMCP meeting, 2 pharmacists discussed medication therapy management (MTM) as it relates to Medicare Part D in a presentation titled MTM: Medicare Part D and Beyond. Jessica Frank,...
Minneapolis—At a pharmacy...
05/23/2011
First Report Managed Care

Advertisement

Advertisement

Advertisement